Prostate Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been confirmed by biopsy to have prostate adenocarcinoma (a specific type of prostate cancer) diagnosed within the last 8 months — including people on active surveillance whose cancer has shown signs of progression and who have had a recent biopsy within 8 months.
• People whose cancer is classified as either "low-risk" or "favourable intermediate-risk" based on specific tumour stage, Gleason score (a measure of cancer aggressiveness), and PSA blood test levels (confirm with trial site for exact classification).
• People aged 18 or older.
• People who are generally active and able to care for themselves, with little to no limitation in daily activities (this is measured using a standard medical scale called ECOG performance status 0–1).
• People who a treating doctor has determined are medically suitable for a type of internal radiation treatment called LDR brachytherapy.
• People whose prostate gland measures 60 cc or smaller, as measured by ultrasound, CT, or MRI within the last 6 months.
• People with an International Prostate Symptom Score (a standard questionnaire about urinary symptoms) of 20 or below — medication called alpha blockers is permitted.
• People who have not used a type of medication called alpha reductase inhibitors within two weeks before being enrolled in the trial.
• People who have not received hormonal therapy for their prostate cancer.
• People who are willing and able to complete a set of study questionnaires about prostate cancer outcomes, urinary symptoms, and sexual health.
• People who have signed the study's informed consent form before joining.

Who may not be able to join:

• People whose cancer has spread to other parts of the body or to lymph nodes, based on clinical or imaging findings.
• People whose cancer has reached a clinical stage higher than T2a (a measure of how far the tumour has grown within or beyond the prostate).
• People with a Gleason score of 4+3 or higher (indicating a more aggressive cancer pattern).
• People with a history of other cancers, unless it was a non-melanoma skin cancer that was adequately treated, or another solid cancer that was fully treated with no signs of return for at least 3 years.
• People who have previously had radical (complete) surgery to remove the prostate, or a procedure called TURP (a surgical procedure to remove part of the prostate).
• People who have previously had radiation treatment to the pelvis, or any prior radiation that would overlap with the area to be treated in this trial.
• People who have received chemotherapy for prostate cancer, or any chemotherapy within the last 3 years.
• People who have previously had cryosurgery (a freezing treatment) on the prostate.
• People who have a current or past bleeding disorder that would make placing small markers in the prostate or performing the brachytherapy procedure unsafe.
• People who have received androgen deprivation therapy (a hormone-reducing treatment) within 6 months before registering for the trial.
• People who have bilateral hip prostheses (artificial replacements in both hips).
• People with serious active health conditions, uncontrolled infections, significant psychiatric illness, severe laboratory abnormalities, or other medical conditions — such as active inflammatory bowel disease or significant urinary symptoms — that the trial investigator determines would prevent safe participation.

Important: Always verify eligibility with the trial site directly before applying.